1H-MRS in patients with multiple sclerosis undergoing treatment with interferon β-1a: Results of a preliminary study

Journal of Neurology Neurosurgery and Psychiatry

Volumn 64, Issue 2, 1998, Pages 204-212

  Sarchielli, P ^a,c   Presciutti, O ^b   Tarducci, R ^b   Gobbi, G ^b   Alberti, A ^a   Pelliccioli, G P ^b   Orlacchio, A ^a   Gallai, V ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Perugia General Hospital   (Italy)

^c POLICLINICO MONTELUCE   (Italy)

Author keywords

Interferon 1a; Multiple sclerosis; Proton magnetic resonance spectroscopy

Indexed keywords

BETA1A INTERFERON; CHOLINE; CREATINE; INOSITOL; N ACETYLASPARTIC ACID; BETA INTERFERON; CREATININE; DIAGNOSTIC AGENT;

ADULT; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOMODULATION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; METABOLITE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TIME; WHITE MATTER; BRAIN; COMPARATIVE STUDY; HOSPITALIZATION; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RECURRENT DISEASE;

ADULT; BRAIN; CHOLINE; CREATININE; DISABILITY EVALUATION; HUMANS; INOSITOL; INTERFERON-BETA; MAGNETIC RESONANCE SPECTROSCOPY; MULTIPLE SCLEROSIS; RECURRENCE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 0031594381     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.64.2.204     Document Type: Article

References (49)

1. Arnold DL, Matthews PM, Francis G, et al. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of the disease. Magn Reson Med 1990;14:154-9.
2. Arnold DL, Matthews PM, Francis G, et al. Proton magnetic resonance spectroscopy imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992;31:235-41.
3. Matthews PM, Francis Gs, Antel JP, et al. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. Neurology 1991;41:1251-6.
4. Miller DH, Austin SJ, Connelly A, et al. Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis. Lancet 1991;337:58-9.
5. Miller D. Magnetic resonance imaging and spectroscopy in multiple sclerosis. Curr Opin Neurol 1995;8:210-5.
6. Pan JW, Hethering HP, Mason GF, et al. Evaluation of multiple sclerosis by high field spectroscopic imaging. Proc Soc Magn Reson Med 1993;3:1552.
7. Confort Gouny S, Vion Dury J, Nicoli F, et al. A multiparametric data analysis showing the potential of localized proton MR spectroscopy of the brain in the metabolic characterization of neurological diseases. J Neurol Sci 1993;118: 123-33.
8. Davie CA, Hawkin CP, Baker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49-58.
9. Davies SEC, Newcombe J, Williams SR, et al. High resolution proton NMR spectroscopy of multiple sclerosis lesions. Neurochemistry 1995;64:742-8.
10. 1H spectroscopic imaging. Ann Neurol 1994;36:157-65.
11. Larsson HBW, Christiansen CP, Jensen M, et al. Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis. Magn Reson Med 1994;22:23-41.
12. Bruhn H, Frahm J, Merboldt KD, et al. Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. Ann Neurol 1992;32:140-50.
13. De Stefano N, Francis G, Antel JP, et al. Reversible decreases of N-acetyl aspartate in the brain of patients with relapsing remitting multiple sclerosis. Proc Soc Magn Reson Med 1993;1:280.
14. Arnold DL, Riess GR, Matthews PM, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994;36:76-82.
15. Matthews PM, Pioro E, Narayanan S, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996;119:715-22.
16. 1H spectroscopic imaging of multiple sclerosis at 4.1 T: effects of β interferon therapy. Proc Soc Magn Reson Med 1995;3:1800.
17. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
19. Jacobs LD, Cookfair DL, Rudic RA, et al, and the Multiple Sclerosis Collaborative Research group. Intramuscular interferon β-1a for disease progression in relapsing remitting multiple sclerosis. Ann Neurol 1996;39:285-94.
20. International Committee of Medical Journal Editors. Statements from the Vancouver Group. BMJ 1991;302:1194.
21. Ormerod IEC, Miller DH, McDonald WI, et al. The role of NMR imaging in the assessment of multiple sclerosis and isolated lesions: a quantitative study. Brain 1987;110:1579-616.
22. Klose U. In vivo proton spectroscopy in presence of eddy currents. Magn Res Med 1990;14:26-30.
23. Press WH, Tenkolsky SA, Vetterling WT, et al. Numerical recipes in C. Cambridge: Cambridge University Press, 1992:656-706.
24. 1H NMR spectra of metabolites in the human. Proc Natl Acad Sci USA 1988;85:1821-5.
25. Koller JK, Zackzek R, Coyle JT. N-acetyl-aspartyl glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J Neurochem 1984;43:1136-42.
26. Tallan HH. Studies of the distribution of N-acetyl-L-aspartic acid in brain. J Biol Chem 1957;224:41-5.
27. Ureniak J, Williams SR, Gadian DG, et al. Proton nuclear magnetic resonance spectroscopy unambiguously identified different neural cell types. J Neurosci 1993;13:981-9.
28. McDonald WI, Miller DH, Barnes D. The pathological and clinical dynamics of multiple sclerosis [review]. J Neuropathol Exp Neurol 1994;53:338-43.
29. McIlwain H, Bachlerad HS. Biochemistry and the central nervous system. 5th ed. Edinburgh: Churchill Livingstone, 1985:314.
30. Zhu G, Allen PS, Koopmans R, et al. A marked elevation of inositol in MS lesions. Proc Soc Magn Reson Med 1992;3:1948.
31. Brenner RE, Munro PMG, Williams SRC, et al. The proton NMR spectrum in acute EAE. The significance of the change in the Cho: Cr ratio. Magn Reson Med 1993;29: 737-45.
32. Brad A, Leibfritz D. Metabolic markers in glial cells for differentiation of the brain tissue. Proc Soc Magn Reson Med 1992;2:649.
33. Berridge MJ. Inositol triphosphate and calcium signaling. Nature 1993;361:315-25.
34. Rudge P, Miller D, Crimlisk H, et al. Does interferon beta cause initial exacerbation of multiple sclerosis? Lancet 1995;345:580.
35. Dayal AS, Jensen MA, Lledo A, et al. Interferon gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology 1995;45:2173-7.
36. Sarchielli P, Russo S, Malà M, et al. Effect of the treatment with IFN-β on the expression of mRNA of TNF-αin patients with multiple sclerosis . Eur J Neurol 1996;3(suppl 59): 103.
37. Milo R, Panitch H. Additive effects of copolymer-1 and interferon β 1b on the immune response to myelin basic protein. J Neuroimmunol 1995;61:185-93.
38. Nohorona A, Toscas A, Arnanson BGW, et al. Interferon-β decrease T cell activation and interferon-γ production in multiple sclerosis. J Neuroimmunol 1993;46:145-54.
39. Norohna A, Toscas A, Arnanson BGW, et al. IFN-beta augments in vivo suppressor function in MS. Neurology 1994; 44(suppl2):A212.
40. Norohna A, Toscas A, Jensen MA. Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 1990;27:207-10
41. Panitch HS, Folus JS, Johnson KP. Recombinant beta interferon inhibits interferon production in multiple sclerosis. Ann Neurol 1987;22:139.
42. Panitch HS, Folus JS, Johnson KP. Recombinant beta interferon inhibits gamma interferon production in multiple sclerosis. Neurology 1989;39:171.
43. Porrini AM, Gambi D, Reder AT. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis. J Neuroimmunol 1995;61:27-34.
44. Shakir S, Byshosh PV, Reder AT. Interferon-β induces interleukin-10 mRNA in mononuclear cells (MNC). Neurology 1994;44(suppl.2):A211-2.
45. Soilu -Hanniken M, Salmi A, Salonen R. Interferon-β downregulates expression of VLA-4 antigen and antagonizes interferon-γ induced expression of HLA-DQ on human peripheral blood monocytes. J Neuroimmunol 1995; 60:99-106.
46. Huynh HK, Oger J, Dorovini-Zis. Interferon-β downregulates interferon-γ-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells. J Neuroimmunol 1995;60:63-73.
47. Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing remitting multiple sclerosis. MRI analysis results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 1993;43:662-7.
48. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
49. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind placebo controlled trial. Neurology 1993;43:655-61.